ATE114476T1 - Tierische zelle mit darin eingeführtem antigenem protein. - Google Patents

Tierische zelle mit darin eingeführtem antigenem protein.

Info

Publication number
ATE114476T1
ATE114476T1 AT88109455T AT88109455T ATE114476T1 AT E114476 T1 ATE114476 T1 AT E114476T1 AT 88109455 T AT88109455 T AT 88109455T AT 88109455 T AT88109455 T AT 88109455T AT E114476 T1 ATE114476 T1 AT E114476T1
Authority
AT
Austria
Prior art keywords
cells
modified
aids
virus
erythrocytes
Prior art date
Application number
AT88109455T
Other languages
English (en)
Inventor
Yves C Nicolau
Garret M Ihler
Original Assignee
Hapgood C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26748809&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE114476(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hapgood C V filed Critical Hapgood C V
Application granted granted Critical
Publication of ATE114476T1 publication Critical patent/ATE114476T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/5432—Liposomes or microcapsules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
    • G01N33/555—Red blood cell
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Botany (AREA)
  • Nanotechnology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
AT88109455T 1987-06-30 1988-06-14 Tierische zelle mit darin eingeführtem antigenem protein. ATE114476T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6828887A 1987-06-30 1987-06-30
US19744588A 1988-05-27 1988-05-27

Publications (1)

Publication Number Publication Date
ATE114476T1 true ATE114476T1 (de) 1994-12-15

Family

ID=26748809

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88109455T ATE114476T1 (de) 1987-06-30 1988-06-14 Tierische zelle mit darin eingeführtem antigenem protein.

Country Status (9)

Country Link
US (1) US5677176A (de)
EP (1) EP0298280B1 (de)
JP (2) JP2728166B2 (de)
AT (1) ATE114476T1 (de)
AU (2) AU1821988A (de)
CA (1) CA1327332C (de)
DE (1) DE3852221T2 (de)
ES (1) ES2067457T3 (de)
IL (1) IL86650A0 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310654A (en) * 1985-07-31 1994-05-10 The Board Of Trustees Of The Leland Stanford Junior University Method for determining virulence of Yersinia
CA1327174C (en) * 1988-10-05 1994-02-22 Youssef Mouneimne Electro-insertion of proteins into animal cell membranes
US5236835A (en) * 1988-10-05 1993-08-17 Hapgood, C.V. Electro insertion of proteins into red cell membranes
WO1990006960A1 (en) * 1988-12-22 1990-06-28 The Dow Chemical Company Improved process for synthesis of heterocyclic polymers
DK0555333T3 (da) * 1990-10-19 1996-04-29 Univ Florida Kunstige virushylstre
US5252348A (en) * 1990-10-19 1993-10-12 Univ. Of Florida Research Foundation, Inc. Artificial viral envelopes
US5753258A (en) * 1990-10-19 1998-05-19 University Of Florida Artificial viral envelopes
PL296382A1 (en) * 1991-02-02 1993-11-02 Nika Health Products Ltd Li Li Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system
DK0517986T3 (da) * 1991-06-14 1998-03-30 Europ Communities Transformerede erythrocytter, fremgangsmåde til fremstilling af samme og deres anvendelse i farmaceutiske præparater
GB9219562D0 (en) 1992-03-11 1992-10-28 Prendergast Kennet F Anti-viral peptides
EP0630407B1 (de) * 1992-03-11 2000-08-02 PRENDERGAST, Kenneth, Francis Anti-virale Fusionspeptide
AU5014393A (en) * 1992-08-13 1994-03-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The The use of cd4 plasma membrane vesicles (pmv) as a therapeutic agent for aids
FI951325L (fi) * 1992-09-22 1995-05-09 Dnx Biotherapeutics Inc Proteiinien kuljetus membraanien välisellä siirrolla ksenogeenisten elinsiirrännäisten esisovittamista varten ja muihin tarkoituksiin
US5840328A (en) * 1994-01-11 1998-11-24 The Liposome Company, Inc. Treatment using arachidonic acid metabolite and particulate formulations
NZ290127A (en) * 1994-07-15 1998-05-27 Lepetit Spa Dinucleoside-5',5'-p1,p2-pyrophosphates; medicaments for treating tumours and viral infections
US5591448A (en) * 1994-11-21 1997-01-07 Tepic; Slobodan Anti-viral therapeutic composition
US5834015A (en) * 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
GB9721901D0 (en) 1997-10-16 1997-12-17 Univ Manchester Particles
AU1734600A (en) * 1998-11-17 2000-06-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Identification of glycosphingolipids that promote hiv-1 entry into cells
HK1040629B (en) 1998-12-23 2005-01-28 Idea Ag Improved formulations for local non-diffusive administration in vivo
PT1031347E (pt) 1999-01-27 2002-09-30 Idea Ag Transporte/imunizacao transnasal com veiculos muitissimo adaptaveis
SI1031346T1 (en) 1999-01-27 2002-08-31 Idea Ag Noninvasive vaccination through the skin
AU5409699A (en) 1999-07-05 2001-01-22 Idea Ag A method for the improvement of transport across adaptable semi-permeable barriers
EP1921451A3 (de) * 2001-05-22 2008-05-28 Cygene, Inc. Komplement-vermittelte Assays für In-vivo- und In-vitro-Verfahren
EA006577B1 (ru) * 2001-10-16 2006-02-24 Киуи Индженьюити Лимитид Контроли чувствительности для серологии крови, приготовленные из модифицированных клеток
US7473432B2 (en) 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
US20050032113A1 (en) * 2003-07-17 2005-02-10 Mitsubishi Pharma Corporation Membrane protein library for proteome analysis and method for preparing same
WO2009118658A2 (en) * 2008-03-26 2009-10-01 University Of Oxford Endoplasmic reticulum targeting liposomes
US8211656B2 (en) 2008-08-13 2012-07-03 The Invention Science Fund I, Llc Biological targeting compositions and methods of using the same
US20100040546A1 (en) * 2008-08-13 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Biological targeting compositions and methods of using the same
US20100042072A1 (en) * 2008-08-13 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Biological targeting compositions and methods of using the same
US20110070154A1 (en) * 2008-08-13 2011-03-24 Hyde Roderick A Artificial cells
PH12012500702A1 (en) 2009-10-08 2012-10-29 Otsuka Pharma Co Ltd An immunoactivation blood perfusion filter for the treatment of malignant tumors
JP6702866B2 (ja) 2013-11-18 2020-06-03 ルビウス セラピューティクス， インコーポレイテッド 合成膜−レシーバー複合体
MA39819A (fr) 2014-04-01 2017-02-08 Rubius Therapeutics Inc Méthodes et compositions d'immunomodulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA806506B (en) * 1979-11-01 1981-09-30 Bio Response Inc A method for production of monoclonal antibodies
DE3218121A1 (de) * 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
FR2564319A1 (fr) * 1984-05-21 1985-11-22 Inst Nat Sante Rech Med Nouvelles compositions de liposomes dotees d'une action specifique vis-a-vis de la proliferation de cellules donnees
US5236835A (en) * 1988-10-05 1993-08-17 Hapgood, C.V. Electro insertion of proteins into red cell membranes

Also Published As

Publication number Publication date
CA1327332C (en) 1994-03-01
AU1821988A (en) 1989-04-27
EP0298280A3 (en) 1990-05-02
DE3852221D1 (de) 1995-01-12
JPH01124382A (ja) 1989-05-17
US5677176A (en) 1997-10-14
EP0298280B1 (de) 1994-11-30
ES2067457T3 (es) 1995-04-01
EP0298280A2 (de) 1989-01-11
AU662154B2 (en) 1995-08-24
JP2825804B2 (ja) 1998-11-18
IL86650A0 (en) 1988-11-30
DE3852221T2 (de) 1995-04-06
JP2728166B2 (ja) 1998-03-18
JPH1072368A (ja) 1998-03-17
AU1942692A (en) 1992-09-24

Similar Documents

Publication Publication Date Title
ATE114476T1 (de) Tierische zelle mit darin eingeführtem antigenem protein.
ES2091861T3 (es) Proteinas antigenicas y vacunas que las contienen para la prevencion de la coccidiosis.
EP0370458A3 (de) Von synthetischer DNS abgeleitete rekombinante HIV-1-Antigene
IE832394L (en) Immunogenic protein or peptide complex vaccine.
DE69033700D1 (de) Il-11 aus säugetier
ATE110412T1 (de) Translation von mrna.
ATE192500T1 (de) Rekombinante viren vektoren zur expression in muskelzellen
EP0158277A3 (de) Implantierbare Zubereitungen von regulatorischen Peptiden mit gesteuerter Freisetzung und Verfahren zur ihrer Herstellung
ES8106407A1 (es) Procedimiento para el tratamiento de superficies hidrofobas
IL89701A0 (en) Recombinant retroviruses,method for the production thereof and pharmaceutical composition containing the same
DK163683D0 (da) Fremstilling af funktionelle humane urokinaseproteiner, dna-sekvens, der koder for et protein omfattende den enzymatiske del af human urokinase, replicerbart udtrykkelsesmedium, der kan udtrykkedna-sekvensen og mikroorganisme eller cellekultur transformeret med mediet
AU6804987A (en) Method for treating plasma and products thereof
ATE446106T1 (de) Pharmazeutische zusammensetzung zur auslösung einer immunantwort bei einem menschen oder einem tier
SE8703225L (sv) Monoklonala antikroppar och peptider anvendbara vid behandling och diagnostisering av hiv-infektioner
DE3061854D1 (en) Process for the preparation of interferon and culture medium composition used in it
GR3007031T3 (de)
Sonozaki et al. The macrophage disappearance reaction: II. Mediation by lymphocytes which lack complement receptors
DK266083A (da) Fremgangsmaade til fremstilling af 2-heterocyclyl-1,3-bis(1h-1,2,4-triazol-1-yl)propan-2-oler eller farmaceutisk acceptable syreadditionssalte deraf
EP0236977A3 (de) Impfstoffe gegen Rindervirus-Diarrhoe und Schweine-Cholera
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
Hale et al. Antigen-liposome modification of target cells as a method to alter their susceptibility to lysis by cytotoxic T lymphocytes.
EP0278487A3 (de) Verfahren zur Inaktivierung hüllhaltiger Viren in mittels einer Zelle in vitro hergestellten Protein-Präparationen
IT8621230A1 (it) Policarbonati ramificati contenenti acidi alifatici policarbossilici o loro derivati e procedimento per la loro preparazione
DK373489A (da) Rekombinante hybrid-partikler med morphologiske egenskaber svarende til antigenet hbsag og omfattende en immunogen sekvens, der inducerer neutraliserende antistoffer rettet mod hiv-retrovirus eller som kan genkendes af saadanne antistoffer, samt vaccine paa basis af saadanne partikler
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee
EEWE Authorization for restitution
REN Ceased due to non-payment of the annual fee
REN Ceased due to non-payment of the annual fee